Home » Newsletters » BioWorld Science

BioWorld Science

May 11, 2012

View Archived Issues

Translation inhibitors show potential in breast cancer models

Researchers detail effects of lisdexamfetamine in patients with depression/chronic fatigue syndrome

Collaborating European universities identify new candidate biomarker of Sjogren's syndrome

Scientists in U.S. design new conformation-selective glutamate receptor inhibitors

Novel protein kinase inhibitors discovered by CrystalGenomics

Research in Spain yields new candidate Gaucher's disease therapies

InterMune creates novel peptides with activity against HCV

New candidate diabetes therapies developed in Japan

New clinical data reported on drug for generalized anxiety disorder and depression

Novel VEGF-A-binding antibody for age-related macular degeneration presented

IAVI, GMI and G&D partner to develop novel AIDS vaccine

Grant supports work at Profectus on vaccines against Nipah and Hendra viruses

Eleven Biotherapeutics secures financing to advance eye disease therapeutics

Clavis Pharma updates on LEAP study

Bionor Pharma reports on Vacc-4x/Endocine study

Chugai Pharmaceutical updates pipeline progress of first quarter 2012

Novartis patents new self-replicating RNA molecules as candidate vaccines

FDA advisory committee issues recommendation on Truvada

First drug approved in E.U. for multiply relapsed/refractory aggressive NHL

Arena and Eisai expand agreement for lorcaserin

Teijin Pharma launches first drip infusion for osteoporosis available in Japan

PolyMedix halts enrollment in PMX-60056 program

NICE issues recommendation on Sanofi drug for prostate cancer

Seikagaku and Kaken report on agreement for lumbar disc herniation treatment candidate

Takeda announces topline vedolizumab results

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.